Driptane

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

oxybutynin (oxybutynin hydrochloride)

Доступна с:

Recipharm Fontaine

ИНН (Международная Имя):

oxybutynin (oxybutynin hydrochloride)

дозировка:

5mg

Фармацевтическая форма:

tablets

Тип рецепта:

Prescription

Характеристики продукта

SUMMARY OF PRODUCTS CHARACTERISTIC
{Oxybutynin
hydrochloride
}
Abbott
Confidential information
1/6
This information is confidential
1.
NAME OF THE MEDICINAL PRODUCT
Driptane, 5 mg tablet
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg of oxybutynin hydrochloride
Excipients with known effect: lactose
For the full list of excipients, see section ‘List of excipients’
3.
PHARMACEUTICAL FORM
Tablet.
Round white, biconvex tablets with a score mark on one side.
The tablet can be divided into equal doses.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Urinary incontinence, imperative urination or urinary frequency in
unstable bladder or as a result of
neurogenic bladder dysfunction (detrusor hyperreflexia) in diseases
such as multiple sclerosis and
spina bifida, or idiopathic detrusor instability (motor urgent urinary
incontinence). It is also used for
an overactive bladder that may occur after surgical operations on the
bladder or prostate, or
accompanying cystitis.
PEDIATRIC POPULATION
Oxybutynin hydrochloride may be used in children older than 5 years
if:
•
urinary incontinence, imperative urination or urination during periods
of rapid unstable bladder
due to idiopathic overactive bladder or neurogenic bladder dysfunction
(detrusor hyperactivity);
•
nocturnal
enuresis
associated
with
detrusor
hyperactivity,
in
combination
with non-drug
methods of with the ineffectiveness other therapy.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
Internally (orally).
ADULTS
The standard dose is 5 mg 2-3 times a day. May increase dose to 5 mg 4
times a day to obtain a
clinical response provided the tolerability of side effects.
ELDERLY PATIENTS
The
half-life
in
elderly
patients
increases,
so
dose
is
2.5
mg
2
times
a
day
(especially
in
immunocompromised patients) usually will be adequate. To obtain the
clinical-ray dose can be
gradually increased to 5 mg 2 times a day, with good tolerability.
CHILDREN (OVER 5 YEARS)
Neurogenic bladder instability: 2.5 mg 2 times a day. To achieve
Clinical effect, the do